Draganfly

Draganfly (DFLYF) Holds ‘Pole Position’ in Race for Drone Supremacy After Chinese Barred from...

STREETWISE REPORTS - March 3, 2020 The company establishes a toehold with U.S. government, homeland security and military contractors, and readies drones to screen for...
Hapbee

Augmentative Wearable Device, Hapbee, Receives Amazing Reviews by Testers.

Originally posted on MartechSeries. The innovative augmentative wearable device, Hapbee, has been giving testers a reason to be happy. With the ability to allow users...

VirnetX (VHC) Scores $440 Million and Citius Pharma (CTXR) Sees Market Expand to Over...

Internet Stock Review Blast from the past scores big! We added VirnetX (VHC) to the Watch List (Patent Stock Review, since shuttered) back in 2010....

Fortress Bio (FBIO) Inches Closer to $3.00 on Major News.

Fortress Bio (FBIO) Inches Closer to $3.00 on Major News. Citius Pharma (CTXR) Inches Closer to the Next Phase III Data Announcement. Citius Pharma Presenting at...
Citius, Biotech Stock Review

Citius (CTXR) Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial

PHASE III PROGRESS October 7th, 2019, Citius Completes 40% - Triggers Data Being Analyzed (is it working?).December 19th, 2019 - Data Analysis Back, Results Positive.February...

Okay, so What’s Next for Citius Pharma (CTXR) $1.16?

Dawson James Broker/Dealer Updates. Price Target Remains at $7.00. "OK, So what’s Next? Topline data from the superior efficacy interim analysis should represent the next...
Citius Pharma

Citius Pharma (CTXR) $1.20. Price Target Upped to $4.00 at HC Wainright.

STREET INSIDER H.C. Wainwright analyst Vernon Bernardino raised the price target on Citius Pharmaceuticals (NASDAQ: CTXR) to $4.00 (from $1.65) while maintaining a Buy rating. The analyst commented,...
coronavirus, biotech stock review

VIDEO: Dyadic (DYAI) CEO Explains What his Industry is Doing to Defeat Coronavirus (FoxNews).

Jan. 27, 2020 - 5:24 - Dyadic International CEO Mark Emalfarb discusses what’s being done to stop the spread of coronavirus and to...
Dyadic

Could Dyadic (DYAI) $5.75 Provide a Solution to Help Mass Produce Vaccines to Battle...

Dyadic (DYAI) has developed a biomanufacturing technology platform, nicknamed C1 which helps to speed the development, lower the manufacturing cost and potentially improve the...
Immunomedics, Biotech Stock Review

Biotech 5 Pack. 5 Biotech Stocks We Expect to Double in 2020.

Our First Newsletter of 2020, We Come out Swinging! Yes, you read it right. Five of our favorite Biotech stocks that have the potential to...

Latest article

Annette L. Redmond Joins Strategic Advisory Board at Sekur Private Data (SWISF).

Former U.S. State Department Deputy Assistant Secretary Decorated intelligence and cybersecurity executive with four decades of U.S. government leadership joins Sekur to advise on secure...

10X Alerts: Sekur Private Data (SWISF) Pushes SekurOne Closer to Market With First International...

Sekur has completed its first domestic and international encrypted calls on SekurOne and launched the platform’s voice, email, messenger, and VPN capabilities on Android...

Could a Record El Niño Ignite the Next Vaccine Trade?

Chikungunya, Dengue Fever, Rift Valley Fever and Zika The Coming El Niño: An Overlooked Catalyst for Vaccine Stocks? Investors obsess over interest rates, tariffs and AI....